Navigation Links
Fourth IMPAKT Breast Cancer Conference
Date:4/25/2012

but many
  • Mucin-1 protein and mRNA expression in breast cancer patients treated with neoadjuvant chemotherapy
  • Independent blinded validation of the genomic index of Sensitivity to Endocrine Therapy (SET)
  • The role of AP-1 in endocrine-resistant breast cancer
  • Advances in breast cancer research help choose the right treatment for the right patient
  • Gene modules and pathological complete response to neoadjuvant chemotherapy in breast cancer: a pooled analysis
  • Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically-defined Luminal A breast cancer
  • Translational studies within the TAMRAD randomized GINECO trial: Evidence for TORC1 activation marker as a predictive factor for everolimus efficacy in metastatic breast cancer
  • Breast cancer in young women is a biologically unique disease that requires customized management strategies

    Highlights on:

    • Challenges, clinical perspectives and implications for biomarker and drug development
    • Making personalized medicine a reality for breast cancer patients: how to speed up the path for reimbursement
    • Intratumor heterogeneity: a challenge for personalized medicine? Can next generation sequencing help solve the problem?
    • Towards a further segmentation of triple negative breast cancer?
    • Can gene signatures become a standard procedure for daily practice? What's new to predict outcome and drug sensitivity?

    Press conference

    Thursday, 3 May 2012, 11:00-12:00 (CEST)

    Hosts:

    Martine Piccart, Jules Bordet Institute, Head of Chemotherapy Unit, Brussels, Belgium, IMPAKT Co-Founder

    Fabrice Andr, Institut de Cancrologie Gustave Roussy, Breast cancer Unit, Department of Medical Oncology, Villejuif, France, IMPAKT2012 Scientific Chair

    Sherene Loi, Institute Jules Bordet, Breast International Group (BIG), Brussels, Belgium, IMPAKT2012 Executive Chair

    Th
    '/>"/>


  • Contact: Vanessa Pavinato
    media@esmo.org
    European Society for Medical Oncology
    Source:Eurekalert

    Page: 1 2 3

    Related biology news :

    1. Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008
    2. BIO-key(R) Announces Fourth Quarter and 2008 Year-End Earnings Release and Conference Call Schedule
    3. Aware, Inc. Reports Fourth Quarter and 2008 Financial Results
    4. BIO-key(R) Reports Profitability for Fourth Quarter and Full Year 2008
    5. Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results
    6. BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability
    7. MiMedx Group, Inc. Announces Release Date for 2010 Fourth Quarter and Full Year Results
    8. AACR hosts Fourth Annual Science of Cancer Health Disparities Conference
    9. Modern genetics answers age-old question on Garrods fourth inborn error of metabolism
    10. Aware, Inc. Reports Fourth Quarter and 2011 Financial Results
    11. IMPAKT -- Breast cancer conference highlights
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
    (Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
    (Date:1/22/2015)... Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication company ... of the Wocket™ smart wallet at CES 2015 in Las ... one of the "11 Hot Products at CES" in a review published ... Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
    Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
    ... turfgrass has become increasingly restricted due to environmental ... and industrial consumption; and contamination of potable water ... need to identify promising water conservation strategies and ... In their ongoing search for ways to improve ...
    ... Washington, D.C. -- Disease statistics buried within patient ... and organized to depict geographic patterns, allowing the discovery ... Penn State geographer. "The use of interactive maps ... to greater insight into complex events like the spread ...
    ... The ELCC Press Program will feature new study ... (embargoed to time of their presentation at ELCC): ... Pemetrexed plus cisplatin with radiation in patients with locally ... therapeutic combination, Screening for lung cancer in organ transplant ...
    Cached Biology News:Common PGR helps creeping bentgrass weather drought 2Visualization of geographic patterns may predict spread of disease 22nd European Lung Cancer Conference 22nd European Lung Cancer Conference 3
    (Date:12/24/2014)... Earlier this year in a June 24 international conference ... Cell Technology Center, LLC ( ASCTC ) focused attention on ... tissue stem cells. His title “Asymmetric Self-Renewal by Distributed ... embodied the essence of his message to congress participants. ...
    (Date:12/24/2014)... On Friday, December 19, 2014, President Obama ... Resolution Appropriations Act of 2015, which for the first ... through the Congressionally Directed Medical Research Programs (CDMRP) administered ... (HA), working in conjunction with its allies on Capitol ...
    (Date:12/24/2014)... 23, 2014 The report provides ... definition, classification, application and industry overview. This report ... cost structure. Production is separated by regions, technology ... materials, equipment, downstream client survey, marketing channels, industry ...
    (Date:12/24/2014)... expects global cell isolation and expansion market to grow at ... about the vital drivers, restraints, trends, opportunities, strategies and challenges ... http://bit.ly/1yUxy0T , According to the report, the global market ... CAGR during near future. It expects this growth to be ...
    Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
    ... PALO ALTO, Calif., Oct. 24 Vivo Ventures, a ... that,James Huang will join the firm as an Executive ... Mr. Huang will,work with Vivo,s portfolio companies while enhancing ... James coming on board and what he will be ...
    ... 24 Cell Therapeutics,Inc. (CTI) (Nasdaq and ... 19th annual AACR-NCI-EORTC Symposium show its bis-platinate ... to currently,marketed platinum agents carboplatin, cisplatin and ... in late 2008. "Bis-platinates represent a ...
    ... is available in German . , Hydrogen fuel ... have so far suffered from being insufficiently competitive. At the ... Strasser has now developed a new class of electrocatalyst that ... active phase of the catalyst consists of nanoparticles with a ...
    Cached Biology Technology:Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 3Platinum-rich shell, platinum-poor core 2
    VEGF Receptor-2, phospho-specific (Tyr996)...
    For the differentiation of mouse embryonic stem cells tooligodendrocytes....
    Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
    IC50: 35 ng/ml · Limit of detection: 8 ng/ml...
    Biology Products: